Trial Profile

Preemptive Therapy with Venetoclax for High Risk Chronic Lymphoid Leukemia Stage a Patients, a Phase II Trial of the FILO

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Venetoclax (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use
Acronyms PREVENE

Most Recent Events

29 Oct 2024 Planned End Date changed from 1 Feb 2028 to 24 Apr 2030.
29 Oct 2024 Status changed from recruiting to active, no longer recruiting.
28 Jun 2021 Planned primary completion date changed from 1 Feb 2021 to 22 Nov 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com